Since the commercialization of the first CAR-T cell therapies, these revolutionary treatments have reshaped the landscape of cancer therapy, offering unprecedented hope to patients with hematologic malignancies. During the webinar, industry and healthcare sector experts from companies including OmniaBio, Yale University, Legend Biotech, and Johnson & Johnson discuss the critical intersection of commercialization strategies and manufacturing technology in advancing the next wave of CAR-T cell therapies to market.

In this webinar transcript, the panelists will discuss these critical aspects to advance CAR-T cell therapy commercialization:

• Navigating commercialization challenges for CAR-T cell therapies through manufacture and final product delivery to patients
• Advancements in regulations and market dynamics accelerating CAR-T commercialization
• CAR-T manufacturing intensification to meet scale and quality demands
• Technology advancements, such as AI, robotics, process analytical technology and rapid release testing to streamline production and improve efficiency

Panelists:
Alexey Bersenev, Emilie Kleiren, John Knighton, Paul Bowles